Pfizer/BioNTech say final results show vaccine 95% effective
An illustration picture shows vials with Covid-19 Vaccine stickers attached and syringes with the logo of US pharmaceutical company Pfizer and German partner BioNTech, on November 17, 2020.
AFP/JUSTIN TALLIS

Pfizer/BioNTech say final results show vaccine 95% effective

(Agence France-Presse) - November 18, 2020 - 9:19pm

WASHINGTON, United States — Pfizer and BioNTech said Wednesday that a completed study of their experimental Covid-19 vaccine showed it was 95% effective.

They said the two-dose vaccine had no serious safety concerns and that the companies will apply for emergency use authorization from US regulators "within days."

The announcement came as coronavirus cases are surging in the US and other parts of the world, and boosted hopes for an end to the pandemic that has upended life around the globe.

"The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic," said Pfizer CEO Albert Bourla.

"With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world," he added.

Pfizer had said last week after a preliminary analysis that its product was more than 90 percent effective.

On Monday another biotech firm involved in the race to develop a vaccine, Moderna, said its own vaccine was 94.5 percent effective, according to a preliminary analysis.

Pfizer has previously said it expected to contact the US Food and Drug Administration to apply for an Emergency Use Authorization by the third week of November.

The FDA had imposed a requirement on COVID-19 vaccine makers of having at least two months of follow-up with volunteers after their second dose, taken 28 days after the first, in order to ensure the drugs are safe.

Moderna developed its vaccine along with the US National Institutes for Health.

Both vaccines use mRNA (messenger ribonucleic acid) technology to deliver genetic material to the body that makes human cells create a protein from the virus.

This trains the immune system to be ready to attack if it encounters SARS-CoV-2.

Other vaccines that are in late-stage trials, such as one being developed by Johnson & Johnson and another by Oxford University and AstraZeneca, use modified viruses to deliver genetic material for the same purpose.

No mRNA vaccines have ever been approved, but Anthony Fauci, the United States' top infectious disease scientist, told AFP Tuesday the technology had now "established itself."

COVID-19 VACCINES NOVEL CORONAVIRUS PFIZER
As It Happens
LATEST UPDATE: January 23, 2021 - 11:34am

Pharma giants Sanofi and GSK said on July 29, 2020, that they have agreed to supply Britain with up to 60 million doses of a potential COVID-19 vaccine. The agreement covers a vaccine candidate developed by France's Sanofi in partnership with the UK's GSK and is subject to a "final contract."

This thread collects some of the major developments in the search for a vaccine to ease the new coronavirus pandemic. (Main photo by AFP/Joel Saget)

January 23, 2021 - 11:34am

Pfizer announces that it will provide up to 40 million of its COVID-19 vaccine doses to poorer countries on a non-profit basis, through the globally-pooled Covax facility.

While dozens of the world's richer countries have begun their vaccination campaigns in a bid to curb the pandemic, coronavirus jabs have been few and far between in the world's poorer nations. — AFP

January 22, 2021 - 5:14pm

The Hungarian government says it had reached a deal to buy large quantities of Russia's Sputnik V coronavirus vaccine, even though it has not been approved by the European Union's medicines watchdog.

"Hungary has concluded with Russia an agreement to buy in three phases large quantities of the Sputnik V vaccine; the contract has been negotiated, and signed during the night," Hungarian Foreign Minister Peter Szijjarto says in a video statement on his Facebook page after meeting the Russian health minister in Moscow. — AFP

January 22, 2021 - 1:44pm

The Brazilian government says that a shipment of two million doses of the British AstraZeneca-Oxford COVID-19 vaccine was finally set to arrive in the country from India.

The delivery Friday would be a much-needed boost to Brazil's vaccination program.

"The two million doses of AstraZeneca should arrive in Brazil Friday in the late afternoon," the ministry of health says in a statement. — AFP

January 20, 2021 - 7:12pm

Japan aims to start vaccinating the general public against the coronavirus in May -- just two months before the postponed Olympics -- following targeted jabs for the most vulnerable, reports said Wednesday.

The Yomiuri Shimbun newspaper said the government is hoping the majority of adults will be vaccinated by July, when the Games are due to open.

The country has agreed with pharmaceutical firms to receive enough doses for all 126 million residents and is working to approve the Pfizer jab as the first to be used in Japan from next month. —  AFP

January 20, 2021 - 8:31am

Mexican authorities are investigating the theft of several coronavirus vaccines from a public hospital, the army said Tuesday, underscoring the challenges of distributing the shots across the crime-plagued country.

Mexico, which has one of the world's highest COVID-19 death tolls, has deployed the military to guard the vaccines and prevent them falling into criminals' hands.

The army said that the stolen vaccines were under the control of a public health institution in a hospital in central Morelos state whose security is overseen by a private company.

"This theft could have been a dishonest act of self-interest by a member of the hospital's vaccination team," it said in a statement. — AFP

Philstar
  • Latest
Latest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

FORGOT PASSWORD?
SIGN IN
or sign in with